ST. PETERSBURG, Russia--High doses of the investigational antiestrogen
toremifene (Fareston) proved safe and effective as palliative therapy in
patients with advanced renal cell carcinoma, say Dr. Michael Gershanovich
and colleagues, of the Professor N. N. Petrov Research Institute of Oncology,
St. Petersburg, and Orion Corporation, Turku, Finland.
Thirty-six renal cancer patients (19 nephrectomized) were started on
toremi-fene, 300 mg/day. One patient was not evaluable for response because
of too short treatment time.
The response rate was 17.1%, including one complete remission lasting
121+ weeks and five partial remissions with a mean duration of 39.8+ weeks.
Ten patients had stable disease for a mean duration of 23.7 weeks (Problems
in Oncology 42:105-109, 1996).
There were no significant differences in response rate between patients
with lung metastases only and those with metastases at other sites with
or without lung metastases.
Among those patients who had pain at the beginning of treatment with
toremifene, 45% achieved total pain control and 20% achieved partial pain
control. Adverse reactions were seen in 10 patients, and led to discontinuation
of the drug in one case.